PRODUCT INFORMATION

Tat-CIRP (trifluoroacetate salt)

Item No. 37446

Synonym: Tat-Cold-inducible RNA Binding Protein
Peptide Sequence: YGRKKRRQRRRGRGFSRGGGDRGYGG-OH
MF: $C_{123}H_{206}N_{56}O_{33} \bullet XCF_3COOH$
FW: 2,997.3
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years

H–Tyr–Gly–Arg–Lys–Lys–Arg–Arg–Gln–Arg–Arg–
Arg–Gly–Arg–Gly–Phe–Ser–Arg–Gly–Gly–Gly–
Asp–Arg–Gly–Tyr–Gly–Gly–OH
• XCF_3COOH

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tat-CIRP (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the Tat-CIRP (trifluoroacetate salt) in water. We do not recommend storing the aqueous solution for more than one day.

Description

Tat-CIRP is a peptide inhibitor of the protein-protein interaction between myeloid differentiation 2 (MD-2), also known as lymphocyte antigen 96 (LY96), and cold-inducible RNA binding protein (CIRP).[1] It binds to MD-2 and disrupts the interaction between MD-2 and CIRP in co-immunoprecipitation assays. *In vivo*, Tat-CIRP (10 and 20 mg/kg) reduces infarct volume in a mouse model of stroke induced by middle cerebral artery occlusion (MCAO). It also reduces infarct volume and decreases the time to pick up and withdraw food with the stroke-affected arm in a rhesus monkey model of thrombosis-induced stroke.

Reference

1. Fang, Z., Wu, D., Deng, J., *et al.* An MD2-perturbing peptide has therapeutic effects in rodent and rhesus monkey models of stroke. *Sci. Transl Med.* **13(597)**, eabb6716 (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM